<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152291</url>
  </required_header>
  <id_info>
    <org_study_id>E-EPA</org_study_id>
    <nct_id>NCT04152291</nct_id>
  </id_info>
  <brief_title>The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism</brief_title>
  <acronym>EPA&amp;LDL</acronym>
  <official_title>The Effect of Ethyl Eicosapentaenoic Acid on Circulating Low-density Lipoproteins and Plasma Lipid Metabolism in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wihuri Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minerva Foundation Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wihuri Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of
      E-EPA is added to their normal diet and lifestyles for a month. Blood samples will be
      collected before the study and at weeks 1 and 4 and also, two weeks after finishing the diet.
      Main study focuses are LDL aggregation susceptibility, lipid composition and proteoglycan
      binding affinity. In addition, important plasma lipid metabolism enzymes and lipid mediated
      resolvins are measured as well as several baseline characteristics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four grams of daily E-EPA was found to significantly decrease atherosclerotic cardiovascular
      diseases in the REDUCE-IT study. In the upcoming study the effect of E-EPA to low-density
      lipoprotein (LDL) aggregation susceptibility is measured using dynamic light scattering
      technique to continuously measure particles size while inducing aggregation. LDL Lipid
      composition is analyzed using electrospray mass spectrometer optimized for lipid
      measurements. Previously is reported that the aggregation susceptibility is affected by the
      lipid composition which is modifiable (Ruuth et. al. Eur.H.Journal 2018). Common disease
      factors such as total cholesterol, LDL, HDL, triglyserides, ApoB-100, ApoA-I, Lp(a) and
      different modified LDL levels are measured. Also, activities of lipid metabolism enzymes like
      PON-1, LCAT, CETP, PLTP and lipid mediated resolvins are looked into. Objective is to
      identify changes and possible pathways that are altered by the increase of E-EPA and to use
      the data to possibly explain the health benefits of EPA.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Baseline measurements are compared to different time points during the study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL Aggregation susceptibility</measure>
    <time_frame>30 days</time_frame>
    <description>Lowering in LDL aggregation susceptibility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lowering total triglycerides</measure>
    <time_frame>30 days</time_frame>
    <description>Lowering of total circulating triglycerides</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EPA incorporation into LDL</measure>
    <time_frame>30 days</time_frame>
    <description>Incorporation of EPA into circulating LDL lipid composition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increases in EPA mediated resolvins</measure>
    <time_frame>30 days</time_frame>
    <description>Increases in circulating resolvins, derived from EPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid metabolizing enzymes</measure>
    <time_frame>30 days</time_frame>
    <description>Changes in activities of circulating lipid metabolizing enzymes such as PON-1, LCAT, PLTP and CETP</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Low-density Lipoproteins Aggregation Susceptibility</condition>
  <condition>Low-density Lipoprotein Lipid Composition</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>E-EPA-diet group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ethyl-Eicosapentaenoic Acid (E-EPA)</intervention_name>
    <description>3,9 grams of EPA is added to participants' normal diet.</description>
    <arm_group_label>E-EPA-diet group</arm_group_label>
    <other_name>E-EPA</other_name>
    <other_name>Icosapentaenoic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy normolipidemic

        Exclusion Criteria:

          -  Prescription of blood thinner medicine

          -  Circulating Low-density lipoprotein &gt; 5mmol/l, Triglycerides &gt;3mmol/l

          -  Chronic use of pain medication

          -  Fish allergy

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katariina Öörni, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wihuri Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wihuri Research Institute</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Ruuth M, Nguyen SD, Vihervaara T, Hilvo M, Laajala TD, Kondadi PK, Gisterå A, Lähteenmäki H, Kittilä T, Huusko J, Uusitupa M, Schwab U, Savolainen MJ, Sinisalo J, Lokki ML, Nieminen MS, Jula A, Perola M, Ylä-Herttula S, Rudel L, Öörni A, Baumann M, Baruch A, Laaksonen R, Ketelhuth DFJ, Aittokallio T, Jauhiainen M, Käkelä R, Borén J, Williams KJ, Kovanen PT, Öörni K. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 2018 Jul 14;39(27):2562-2573. doi: 10.1093/eurheartj/ehy319.</citation>
    <PMID>29982602</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.</citation>
    <PMID>30415628</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wihuri Research Institute</investigator_affiliation>
    <investigator_full_name>Katariina Öörni</investigator_full_name>
    <investigator_title>Group leader, Ph.D</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>E-EPA</keyword>
  <keyword>LDL aggregation susceptibility</keyword>
  <keyword>Lipidomics</keyword>
  <keyword>Resolvins</keyword>
  <keyword>PON-1</keyword>
  <keyword>LCAT</keyword>
  <keyword>PLTP</keyword>
  <keyword>CETP</keyword>
  <keyword>Proteglycan binding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

